EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
A1C-3	05336163190	7613336000739Y

Intended Use:
In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood or hemolysate on cobas c and COBAS INTEGRA systems. HbA1c determinations are useful monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes

Product Name	Cat. No.	Basic UDI-DI
A1C-3	05336180190	761333600075A4

Intended Use:
In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood and hemolysates prepared from whole blood on the cobas c 111 system. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

Product Name	Cat. No.	Basic UDI-DI
A1CX3	07559674190	761333600479AY
A1CX3	08056668190	7613336005009W
A1CX3	08445699190	7613336001189V

Intended Use:
In vitro test for the quantitative determination of mmol/mol hemoglobin A1c (IFCC) and % hemoglobin A1c (DCCT/NGSP) in whole blood or hemolysate on cobas c systems. HbA1c determinations are useful for monitoring of long-term blood glucose control in individuals with diabetes mellitus. Moreover, this test is to be used as an aid in diagnosis of diabetes and identifying patients who may be at risk for developing diabetes.

Digitally signed by Lazari Cristina
Date: 2024.12.19 16:07:22 EET
Reason: MoldSign Signature
Location: Moldova

Roche Diagnostics GmbH; Sandhofer Straße 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Product Name	Cat. No.	Basic UDI-DI
PreciControl HbA1c norm	05479207190	761333600099AJ
PreciControl HbA1c norm	05991323922	761333600172A3

Intended Use:
PreciControl HbA1c norm is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the value sheets.

Product Name	Cat. No.	Basic UDI-DI
PreciControl HbA1c path	05912504190	761333600375AK
PreciControl HbA1c path	05991331922	761333600173A5

Intended Use:
PreciControl HbA1c path is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the value sheets.

Product Name	Cat. No.	Basic UDI-DI
C.f.a.s. HbA1c	04528417190	761333600282AB

Intended Use:
C.f.a.s. (Calibrator for automated systems) HbA1c is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the enclosed value sheets.

Risk Class: ☐ *A* ☐ *B* ☒ *C* ☐ *D*

Conformity Route:
☐ *Self-Declaration of Conformity (Class A)*
☐ *Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)*
☒ *Technical Documentation Assessment Class B/C – Annex IX*
☐ *Technical Documentation Assessment Class D – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX*
☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*

Certificates:
☒ *EU QM Certificate No.: V12 010283 0639*
☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*

Other:
☐ *Common Specifications:*

Notified Body (NB) Name: *TÜV Süd Product Service GmbH*
NB Address: *Ridlerstraße 65*
80339 Munich
Germany
NB Ident. No.: *0123*

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 19 February 2024

Roche Diagnostics GmbH

i.V./*on behalf of the company*

DocuSigned by:
Christina Schmid
E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**A1CD** Hemolyzing reagent
Art.-Nr./*Cat. No.*:	**08463107190**
Beschreibung/*Description*:	Das Hämolysereagenz dient als Diluent für den Tina-quant Hemoglobin A1c Gen.3 Test auf **cobas c** Systemen. *The hemolyzing reagent is used as diluent for the Tina-quant Hemoglobin A1c Gen.3 assay on **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 9 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Acid Wash**
Art.-Nr./*Cat. No.*:	**08302723190**
Beschreibung/*Description*:	Acid Wash wird als saure Waschlösung für Reagenzküvetten auf Roche/Hitachi **cobas c** Systemen verwendet. *Acid Wash is used as acid wash solution for reaction cells on the Roche/Hitachi **cobas c** analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 7 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*
ppa. Dr. Beate Bonefeld

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**ALB2** Albumin Gen.2
Art.-Nr./*Cat. No.*:	**08056692190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von Albumin in Humanserum und -plasma mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of albumin in human serum and plasma on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**ALP2** Alkaline phosphatase acc. to IFCC Gen.2
Art.-Nr./*Cat. No.*:	**08056757190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung der alkalischen Phosphatase in Humanserum und -plasma mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of alkaline phosphatase in human serum and plasma on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 22 October 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:	Roche Diagnostics GmbH
Address:	Sandhofer Strasse 116 68305 Mannheim Germany
Single Registration Number:	DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
ALTP2	07049480190	761333600623AF
ALTP2	08104697190	761333600646AT
ALTP2	08104697214	761333602943BJ

Intended Use:
In vitro test for the quantitative determination of alanine aminotransferase (ALT) with pyridoxal phosphate activation in human serum and plasma on cobas c systems.

Risk Class: ☐ A ☒ B ☐ C ☐ D

Conformity Route:

☐ Self-Declaration of Conformity (Class A)

☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)

☒ Technical Documentation Assessment Class B/C – Annex IX

☐ Technical Documentation Assessment Class D – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX

☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:

☒ EU QM Certificate No.: *V12 010283 0639*

☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Roche Diagnostics GmbH; Sandhofer Straße 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Dr. Claudia Fleischer; Dr. Virginia Bastian
Aufsichtsratsvorsitzender: Dr. Thomas Schinecker

Notified Body (NB) Name:	TÜV Süd Product Service GmbH
NB Address:	Ridlerstraße 65 80339 Munich Germany
NB Ident. No.:	0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 10 October 2024

Roche Diagnostics GmbH

i.V./*on behalf of the company*

DocuSigned by:
Klaus Riebel
5E57330EEFE04C4...

Dr. Klaus Riebel
Network Lead Site Head Penzberg & Cape Town

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:
Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**AMYL2** α-Amylase EPS ver.2
Art.-Nr./*Cat. No.*:	**08056811190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung der α-Amylase in Humanserum, -plasma und -urin mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of α-amylase in human serum, plasma and urine on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 22 October 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:	Roche Diagnostics GmbH
Address:	Sandhofer Strasse 116 68305 Mannheim Germany
Single Registration Number:	DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
ASTP2	07049625190	761333600624AH
ASTP2	08104719190	761333600647AV
ASTP2	08104719214	761333602922BA

Intended Use:
In vitro test for the quantitative determination of aspartate aminotransferase (AST) with pyridoxal phosphate activation in human serum and plasma on cobas c systems.

Risk Class: ☐ A ☒ B ☐ C ☐ D

Conformity Route:

☐ Self-Declaration of Conformity (Class A)

☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)

☒ Technical Documentation Assessment Class B/C – Annex IX

☐ Technical Documentation Assessment Class D – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX

☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:

☒ EU QM Certificate No.: *V12 010283 0639*

☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):

Other: ☐ Common Specifications:

Roche Diagnostics GmbH; Sandhofer Straße 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Dr. Claudia Fleischer; Dr. Virginia Bastian
Aufsichtsratsvorsitzender: Dr. Thomas Schinecker

Notified Body (NB) Name:	TÜV Süd Product Service GmbH
NB Address:	Ridlerstraße 65 80339 Munich Germany
NB Ident. No.:	0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 10 October 2024

Roche Diagnostics GmbH

i.V./*on behalf of the company*

DocuSigned by:
Klaus Riebel
5E57330EEFE04C4...

Dr. Klaus Riebel
Network Lead Site Head Penzberg & Cape Town

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:
Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Basic Wash**
Art.-Nr./*Cat. No.*:	**08302545190**
Beschreibung/*Description*:	Basic Wash wird als alkalische Waschlösung für Reagenzküvetten auf Roche/Hitachi **cobas c** Systemen verwendet. *Basic Wash is used as alkaline wash solution for reaction cells on the Roche/Hitachi **cobas c** analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 7 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*
ppa. Dr. Beate Bonefeld

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**BILD2** Bilirubin Direct Gen.2 (Jendrassik-Grof) Bilirubin Direct Gen.2 (Doumas standardization)
Art.-Nr./*Cat. No.*:	**08056951190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von direktem Bilirubin in Humanserum und -plasma mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of direct bilirubin in human serum and plasma on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**BILT3** Bilirubin Total Gen.3
Art.-Nr./*Cat. No.*:	**08056960190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von Gesamtbilirubin in Serum und Plasma von Erwachsenen und Neugeborenen mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of total bilirubin in serum and plasma of adults and neonates on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH

Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	Cat. No.	Basic UDI-DI
Elecsys CA 19-9	11776193122	761333600730AH
Elecsys CA 19-9	11776193214	761333602081AD
Elecsys CA 19-9	07027028190	761333600799BM
Elecsys CA 19-9	07027028214	761333602050A2

Intended Use:
Immunoassay for the in vitro quantitative determination of CA 19-9 in human serum and plasma. The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	Cat. No.	Basic UDI-DI
CA 19-9 CalSet	11776215122	761333600732AM

Intended Use:
CA 19-9 CalSet is used for calibrating the quantitative Elecsys CA 19-9 assay on cobas e immunoassay analyzers.

Risk Class: ☐ A ☐ B ☒ C ☐ D

Conformity Route:

☐ Self-Declaration of Conformity (Class A)

☐ Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)

☒ Technical Documentation Assessment Class B/C – Annex IX

☐ Technical Documentation Assessment Class D – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX

☐ Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX

Roche Diagnostics GmbH; Sandhofer Straße 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

☐ Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX

Certificates:	☒ EU QM Certificate No.: *V12 010283 0639*
	☐ EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):
Other:	☐ Common Specifications:
Notified Body (NB) Name:	TÜV Süd Product Service GmbH
NB Address:	Ridlerstraße 65 80339 Munich Germany
NB Ident. No.:	0123

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 12 August 2024

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
485913ABEB04408...

Dr. Peer Lorenz
Site Quality Head / Network Lead, Mannheim

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address: Roche Diagnostics GmbH
Abt./Dept. Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**CA2** Calcium Gen.2
Art.-Nr./*Cat. No.*:	**08057427190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von Calcium in Humanserum, -plasma und -urin mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of calcium in human serum, plasma and urine on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Roche Professional Diagnostics Sandhofer Straße 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/*Product name*:	**C.f.a.s. CK-MB**
Art.-Nr./*Id. No.*:	**11447394**
Beschreibung/*Description*:	C.f.a.s. (Calibrator for automated systems) CK-MB wird zur Kalibration von Roche-Methoden für die quantitative Bestimmung von CK-MB an klinisch-chemischen Analysenautomaten von Roche wie in den Werteblättern angegeben verwendet. *C.f.a.s. (Calibrator for automated systems) CK-MB is for use in the calibration of Roche methods for the quantitative determination of CK-MB on Roche clinical chemistry analyzers as specified in the value sheets.*

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 13.07.2011
Roche Diagnostics GmbH

ppa./*on behalf of the company*
Dr. M. Thein
Head of Quality
Roche Professional Diagnostics

i. V./*on behalf of the company*
Dr. B. Rauschel
Head of Quality Control Penzberg
Roche Diagnostics Global Operations

Kontaktadresse/*Contact address*: Roche Professional Diagnostics
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH; Werk Penzberg; Nonnenwald 2; D 82377 Penzberg; Telefon +49 8856 60 0; Telefax +49 8856 60 3896

Roche

Diagnostics

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Roche Centralized Diagnostics Sandhofer Straße 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/*Product name*:	**C.f.a.s. HbA1c**
Art.-Nr./*Id. No.*:	04528417
Beschreibung/*Description*:	C.f.a.s. (Calibrator for automated systems) HbA1c wird zur Kalibration von quantitativen Roche-Methoden an klinisch-chemischen Analysenautomaten von Roche wie im beiliegenden Werteblatt angegeben verwendet. *C.f.a.s. (Calibrator for automated systems) HbA1c is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the enclosed value sheet.*

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 14.10.2005
Roche Diagnostics GmbH

ppa./*on behalf of the company*

Dr. M. Thein
Head of Quality Management &
Regulatory Affairs
Centralized Diagnostics

i. V./*on behalf of the company*

A. Schenkel
Head of Quality Assurance
Centralized Diagnostics

Kontaktadresse/*Contact address*: Roche Centralized Diagnostics
Abt./*Dept.* Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

Roche Diagnostics GmbH
Roche Centralized Diagnostics
Sandhofer Strasse 116
D-68305 Mannheim
Telefon +49-621-759 0
Telefax +49-621-759 20 90

Registergericht Mannheim
HRB 3962
Aufsichtsrat:
Dr. Franz B. Humer, Vorsitzender

Geschäftsführung:
Dr. Jürgen Schwiezer, Vorsitzender
Dr. Manfred Baier, Staffan Ek,
Dr. Volker Pfahlert,
Burkhard G. Pipel,
Peter-Claus Schiller,
Prof. Dr. Dr. Klaus Strein

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Roche Professional Diagnostics Sandhofer Straße 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/*Product name*:	**C.f.a.s. Lipids**
Art.-Nr./*Id. No.*:	**12172623**
Beschreibung/*Description*:	C.f.a.s. (Calibrator for automated systems) Lipids wird zur Kalibration von quantitativen Roche-Methoden an klinisch-chemischen Analysenautomaten *C.f.a.s. (Calibrator for automated systems) Lipids is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the value sheets.*

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 13.07.2011
Roche Diagnostics GmbH

ppa./*on behalf of the company*

Dr. M. Thein
Head of Quality
Roche Professional Diagnostics

i. V./*on behalf of the company*

Dr. B. Rauschel
Head of Quality Control Penzberg
Roche Diagnostics Global Operations

Kontaktadresse/*Contact address*: Roche Professional Diagnostics
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH; Werk Penzberg; Nonnenwald 2; D 82377 Penzberg; Telefon +49 8856 60 0; Telefax +49 8856 60 3896

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Roche Professional Diagnostics Sandhofer Straße 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie (bei rezepturgleichen Produkten)
Roche Diagnostics GmbH declares that the product/the product line (in case of products manufactured by identical recipes)

Produktname/*Product name*:	**Calibrator for automated systems**
Art.-Nr./*Id. No.*:	**10759350**
Beschreibung/*Description*:	Calibrator for automated systems (C.f.a.s.) wird zur Kalibration von quantitativen Roche-Methoden an klinisch-chemischen Analysengeräten von Roche wie in den Werteblättern angegeben verwendet. *Calibrator for automated systems (C.f.a.s.) is for use in the calibration of quantitative Roche methods on Roche clinical chemistry analyzers as specified in the value sheets.*

auf das/die sich diese Erklärung bezieht, den Forderungen der EG-Richtlinie 98/79/EG des Rates vom 27. Oktober 1998 (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) über In-vitro-Diagnostica entspricht.
to which this declaration relates fulfils the requirements of EC Directive 98/79/EC of the Council of 27 October 1998 (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market) concerning in-vitro diagnostic devices.

Mannheim, 26.10.2011

Roche Diagnostics GmbH

ppa./*on behalf of the company*	i. V./*on behalf of the company*
Dr. M. Thein Head of Quality Roche Professional Diagnostics	Dr. B. Rauschel Head of Quality Control Penzberg Roche Professional Diagnostics

Kontaktadresse/*Contact address*: Roche Professional Diagnostics
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Straße 116
D-68305 Mannheim
Fax: +49 621/759 1448

Roche Diagnostics GmbH Diagnostics Division

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49 621 759 0; Telefax +49 621 759 2890

Sitz der Gesellschaft: Mannheim - Registergericht: AG Mannheim HRB 3962 - Geschäftsführung: Thomas Schmid, Sprecher; Edgar Vieth - Aufsichtsratsvorsitzender: Dr. Severin Schwan

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**CHOL2** Cholesterol Gen.2
Art.-Nr./*Cat. No.*:	**08057443190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von Cholesterin in Humanserum und -plasma mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of cholesterol in human serum and plasma on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 21 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**CKMB** Creatine Kinase-MB
Art.-Nr./*Cat. No.*:	**08057486190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung der katalytischen Aktivität der MB-Untereinheit der Creatinkinase (CK-MB) in Humanserum und -plasma mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of the catalytic activity of creatine kinase MB subunit (CK-MB) in human serum and plasma on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 22 October 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliament and Council of 27 October 1998
und/*and*
gemäß Anhang VI der Richtlinie 2011/65/EU des Europäischen Parlaments und des Rates vom 8. Juni 2011
as per Annex VI of Directive 2011/65/EU of the European Parliament and Council of 8 June 2011

Hersteller/*Manufacturer*:	Hitachi High-Technologies Corporation 1-24-14 Nishi-Shimbashi, Minato-ku Tokyo 105-8717 Japan
Authorized Representative:	Roche Diagnostics GmbH Sandhofer Strasse 116 68305 Mannheim Germany

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Cl Electrode**
Art.-Nr./*Id. No.*:	**03246353001**
Beschreibung/*Description*:	Ionen-selektive Elektrode in Kombination mit ISE Modulen der Roche/Hitachi Analysenautomaten zur quantitative Bestimmung von Chlorid in Serum, Plasma oder Urin. *Ion-selective electrode to be used with ISE modules of Roche/Hitachi analyzer for quantitative determination of chloride in serum, plasma or urine.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

und/*and*
Ab Serien-Nr./*Starting with Serial No.*: E3000

Roche Diagnostics GmbH; Sandhofer Strasse 116; 68305 Mannheim; Germany, Telefon +49-621-759-0; Telefax +49-621-759-2890

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 2011/65/EU inklusive Artikel 4 des Europäischen Parlaments und des Rates vom 8. Juni 2011 betreffend Beschränkung der Verwendung bestimmter gefährlicher Stoffe gemäss Anhang II (Blei, Quecksilber, Cadmium, Sechswertiges Chrom, Polybromierte Biphenyle and Polybromierte Diphenylether) in Elektro- und Elektronikgeräten (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfills the requirements of Directive 2011/65/EU including Article 4 of the European Parliament and Council of 8 June 2011 on the restriction of the use of certain hazardous substances according Annex II (lead, mercury, hexavalent chromium, cadmium, polybrominated biphenyls and polybrominated diphenyl ethers) in electrical and electronic equipment (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 27 July 2016

Roche Diagnostics GmbH

ppa./*on behalf of the company*

i.V.

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Peter Martin
Senior Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
68305 Mannheim
Germany

Roche Diagnostics GmbH; Sandhofer Strasse 116; 68305 Mannheim; Germany, Telefon +49-621-759-0; Telefax +49-621-759-2890

EU Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: Roche Diagnostics GmbH
Address: Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys C-Peptide	03184897190	761333600931AV
Elecsys C-Peptide	03184897214	761333602044A7

Intended Use:
Immunoassay for the in vitro quantitative determination of C-peptide in human serum, plasma and urine. The assay is intended for use as an aid in the diagnosis and treatment of patients with abnormal insulin secretion. The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys C-Peptide	07027168190	761333600993BK
Elecsys C-Peptide	07027168214	761333602053A8

Intended Use:
Immunoassay for the in vitro quantitative determination of C-peptide in human serum, plasma and urine. The assay is intended for use as an aid in the diagnosis and treatment of patients with abnormal insulin secretion. The electrochemiluminescence immunoassay "ECLIA" is intended for use on cobas e immunoassay analyzers.

Product Name	**Cat. No.**	**Basic UDI-DI**
C-Peptide CalSet	03184919190	761333600932AX

Intended Use:
C-Peptide CalSet is used for calibrating the quantitative Elecsys C-Peptide assay on cobas e immunoassay analyzers.

Risk Class: ☐ *A* ☒ *B* ☐ *C* ☐ *D*

Roche Diagnostics GmbH; Sandhofer Straße 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Conformity Route:	☐ *Self-Declaration of Conformity (Class A)* ☐ *Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)* ☒ *Technical Documentation Assessment Class B/C – Annex IX* ☐ *Technical Documentation Assessment Class D – Annex IX* ☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX* ☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX* ☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*
Certificates:	☒ *EU QM Certificate No.: V12 010283 0639* ☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*
Other:	☐ *Common Specifications:*
Notified Body (NB) Name: *NB Address:* *NB Ident. No.:*	*TÜV Süd Product Service GmbH* *Ridlerstraße 65* *80339 Munich* *Germany* *0123*

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 30 March 2023

Roche Diagnostics GmbH

i.V./*on behalf of the company*

DocuSigned by:
Christina Schmid
E3965E80F3E840E...

Dr. Christina Schmid
Head of Pre-Market Quality Core Lab

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Global Head of Regulatory Affairs, Core Lab

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang III der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998
as per Annex III of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998

Hersteller/*Manufacturer:*	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**CREJ2** Creatinine Jaffe Gen.2
Art.-Nr./*Cat. No.*:	**08057532190**
Beschreibung/*Description*:	In-vitro-Test zur quantitativen Bestimmung von Creatinin in Humanserum, -plasma und -urin mit Roche/Hitachi **cobas c** Systemen. *In vitro test for the quantitative determination of creatinine in human serum, plasma and urine on Roche/Hitachi **cobas c** systems.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 16 November 2018

Roche Diagnostics GmbH

ppa./*on behalf of the company*

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890